focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,172.00
Bid: 12,168.00
Ask: 12,170.00
Change: -74.00 (-0.60%)
Spread: 2.00 (0.016%)
Open: 12,240.00
High: 12,306.00
Low: 12,132.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

18 Jun 2014 10:00

RNS Number : 9170J
AstraZeneca PLC
18 June 2014
 



Transaction by Person Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

 

On 16 June 2014, the interest of Mr Marc Dunoyer, a person discharging managerial responsibilities, in the ordinary shares of AstraZeneca PLC changed as detailed below.

 

The change in interest relates to the vesting of a previously announced award of restricted shares made to Mr Dunoyer in August 2013. The award vests in three tranches over three years.

 

After sufficient shares were withheld to satisfy certain tax obligations arising on the vesting, Mr Dunoyer has become beneficially entitled to and has received 4,824 shares into a personal brokerage account in respect of the first tranche of the award.

 

For tax purposes, the fair market value of the shares at vest was 4385 pence per share being the closing price of AstraZeneca ordinary shares on the last trading day preceding the vesting day.

 

 

A C N Kemp

Company Secretary

18 June 2014

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUWSWRSUANARR
Date   Source Headline
24th Apr 20207:00 amRNSLynparza shows overall survival in prostate cancer
17th Apr 202011:00 amRNSChanges to arrangements for AGM
14th Apr 20207:00 amRNSKoselugo (selumetinib) approved in the US for NF1
14th Apr 20207:00 amRNSTagrisso adjuvant trial overwhelmingly positive
2nd Apr 20207:00 amRNSAstraZeneca divestment of Movantik completed
1st Apr 20203:00 pmRNSTotal Voting Rights
31st Mar 20207:00 amRNSDirector/PDMR Shareholding
30th Mar 20207:01 amRNSImfinzi approved in US for small cell lung cancer
30th Mar 20207:00 amRNSFarxiga CKD trial early stop for positive efficacy
26th Mar 20207:00 amRNSLokelma approved in Japan for hyperkalaemia
26th Mar 20207:00 amRNSDirector/PDMR Shareholding
24th Mar 20204:41 pmRNSSecond Price Monitoring Extn
24th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 202012:02 pmRNSPrice Monitoring Extension
23rd Mar 20204:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20204:36 pmRNSPrice Monitoring Extension
23rd Mar 202012:08 pmRNSSecond Price Monitoring Extn
23rd Mar 202012:03 pmRNSPrice Monitoring Extension
20th Mar 202010:20 amRNSSecond Price Monitoring Extn
20th Mar 202010:15 amRNSPrice Monitoring Extension
20th Mar 20207:00 amRNSDirector/PDMR Shareholding
19th Mar 20207:00 amRNSLynparza granted orphan drug designation in Japan
17th Mar 20207:00 amRNSImfinzi confirmed overall survival in CASPIAN
13th Mar 20204:35 pmRNSPrice Monitoring Extension
12th Mar 202011:00 amRNSNotice of AGM
12th Mar 20207:00 amRNSUpdate on Phase III GY004 trial for cediranib
10th Mar 20207:00 amRNSDirector/PDMR Shareholding
6th Mar 20207:00 amRNSUpdate on Phase III DANUBE trial in bladder cancer
4th Mar 20207:00 amRNSFiling of Form 20-F with SEC
3rd Mar 202011:00 amRNSAnnual Financial Report
2nd Mar 20203:00 pmRNSTotal Voting Rights
2nd Mar 20207:00 amRNSDivestment of hypertension medicines completed
27th Feb 20207:00 amRNSDirector/PDMR Shareholding
25th Feb 20207:00 amRNSAstraZeneca divests global rights to Movantik
19th Feb 20207:00 amRNSDirector/PDMR Shareholding
14th Feb 20207:00 amRNSAZN: Full-year and Q4 2019 results
3rd Feb 20203:00 pmRNSTotal Voting Rights
27th Jan 20207:00 amRNSEnhertu Phase II trial met primary endpoint
27th Jan 20207:00 amRNSBrilinta met primary endpoint in stroke trial
27th Jan 20207:00 amRNSAstraZeneca divests hypertension medicines
27th Jan 20207:00 amRNSAstraZeneca to recover brazikumab (MEDI2070)
20th Jan 20207:00 amRNSFDA grants Lynparza Priority Review for PROfound
20th Jan 20207:00 amRNSImfinzi, tremelimumab granted ODD in liver cancer
13th Jan 20207:01 amRNSLynparza granted FDA Priority Review for PAOLA-1
13th Jan 20207:00 amRNSUpdate on Epanova Phase III STRENGTH trial
6th Jan 20207:01 amRNSFarxiga granted FDA heart failure Priority Review
6th Jan 20207:00 amRNSLokelma approved in China for hyperkalaemia
2nd Jan 20203:00 pmRNSTotal Voting Rights
30th Dec 20197:00 amRNSUS FDA approved Lynparza for pancreatic cancer
23rd Dec 20197:00 amRNSTriple-combination approved in China for COPD

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.